Abionyx Pharma Partners With Lille Hospital to Study CER-001 in Burn Patients
Abionyx Pharma partnered with Lille University Hospital to study CER-001 in severe burn patients.
Related stories
Magle Chemoswed Swings to Q3 Operating Loss of SEK 45 Million
M impact | EQUITY | Nov 04, 2026, 08:08 AM UTC
Demant Q3 Revenue Rises; Forecasts Growth; Resumes Buybacks
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
SK Reit Q3 Net Profit Falls 19.6% Quarter on Quarter
SK Reit’s third-quarter 2026 net profit fell 19.6% from the previous quarter.
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
SI-BONE Posts 14.5% Revenue Growth as Procedure Volume Rises 19.5%
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
Hedera Group Reports Third-Quarter 2026 Results
Hedera Group AB reported third-quarter net sales, down year over year.
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
LGI Homes Q3 Revenue Rises, Orders Fall; Credit Line Extended
M impact | EQUITY | Nov 04, 2026, 08:00 AM UTC